Idiopathic Parkinson Disease
39
2
4
23
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
7.7%
3 terminated out of 39 trials
88.5%
+2.0% vs benchmark
15%
6 trials in Phase 3/4
43%
10 of 23 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 23 completed trials
Clinical Trials (39)
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Phase 2a Study of VTX3232 in Parkinson's Disease
Physiological Effects of Nutritional Support in Patients With Parkinson's Disease
Reliability and Validity Study of the Turkish Version of the Parkinson's Disease Dyskinesia Scale (PDYS-26)
Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA
Prolactin, Inflammation, and Parkinson's Severity
Adhesion and Safety of Rotigexole Compared to Neupro®
FDOPA PET and Nutritional Support in Parkinson's Disease
Effects of Sensory-Motor Integration Training in Patients with Idiopathic Parkinson's Disease
A Study to Evaluate in Patients With Parkinsonian Type Disorders
Intravenous Plasma Treatment for Parkinson's Disease
A Prospective Study to Evaluate the Correlation Between Oculometric Measurements and Clinical Endpoints in PD Patients
Sleep, Awake & Move - Part I
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
Molecular Pathology and Neuronal Networks in LRRK2 Parkinson's Disease
Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)
Voice Treatment for Parkinson's Disease
Effect of Safinamide on Parkinson's Disease Related Chronic Pain
The Natural History of Parkinson's Disease-associated Spinal Disorders
Study to Assess the Safety of MRx0029 or MRx0005 Compared to Placebo, in People With Parkinson's